{"id":"W4391559535","doi":"10.1200/jco.2024.42.36_suppl.439572","title":"Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Bortezomib; Daratumumab; Dexamethasone; Multiple myeloma; Internal medicine; Refractory (planetary science); Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003937832,0.001737494,0.002642911,0.0004103145,0.0004626801,0.001251134,0.001386863,0.001776149,0.008534218],"category_scores_gemma":[0.002735949,0.0008218365,0.002185024,0.000423911,0.001370475,0.001191107,0.0006798017,0.004801607,0.001437483],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00123314,"about_ca_system_score_gemma":0.001856702,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001239154,"about_ca_topic_score_gemma":0.003279644,"domain_scores_codex":[0.9985368,0.001010797,0.0000690385,0.000151762,0.000083582,0.0001480497],"domain_scores_gemma":[0.9980265,0.0005611549,0.0004124748,0.0001429675,0.00008904287,0.0007678395],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9769441,0.008376299,0.0005952895,0.0002969023,0.001029661,0.00002902159,0.00004432744,0.0004172719,0.001831203,0.0000841898,0.001249697,0.009101934],"study_design_scores_gemma":[0.9165842,0.07940045,0.001760534,0.00002354135,0.0007106409,0.00004397164,0.00002250225,0.0002395006,0.0003567525,0.0001410866,0.0007049112,0.00001186444],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9792488,0.004883594,0.0008180313,0.001209001,0.0005826022,0.005256189,0.00404042,0.0001489026,0.003812556],"genre_scores_gemma":[0.980451,0.002409607,0.001920359,0.001603947,0.0004027968,0.004643116,0.004654331,0.00006787984,0.003847079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008534218,"threshold_uncertainty_score":0.02854979,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1014030987003725,"score_gpt":0.4550800140791745,"score_spread":0.3536769153788019,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}